

RESEARCH

Open Access



Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

Stefano Guadagni^{1*}, Francesco Masedu¹, Giammaria Fiorentini², Donatella Sarti², Caterina Fiorentini³, Veronica Guadagni⁴, Panagiotis Apostolou⁵, Ioannis Papatirou⁶, Panagiotis Parsonidis⁵, Marco Valenti¹, Enrico Ricevuto¹, Gemma Bruera¹, Antonietta R. Farina¹, Andrew R. Mackay^{1†} and Marco Clementi^{1†}

Abstract

Background: Patients with unresectable recurrent rectal cancer (RRC) or colorectal cancer (CRC) with liver metastases, refractory to at least two lines of traditional systemic therapy, may receive third line intraarterial chemotherapy (IC) and targeted therapy (TT) using drugs selected by chemosensitivity and tumor gene expression analyses of liquid biopsy-derived circulating tumor cells (CTCs).

Methods: In this retrospective study, 36 patients with refractory unresectable RRC or refractory unresectable CRC liver metastases were submitted for IC and TT with agents selected by precision oncotherapy chemosensitivity assays performed on liquid biopsy-derived CTCs, transiently cultured *in vitro*, and by tumor gene expression in the same CTC population, as a ratio to tumor gene expression in peripheral mononuclear blood cells (PMBCs) from the same individual. The endpoint was to evaluate the predictive accuracy of a specific liquid biopsy precision oncotherapy CTC purification and *in vitro* culture methodology for a positive RECIST 1.1 response to the therapy selected.

Results: Our analyses resulted in evaluations of 94.12% (95% CI 0.71–0.99) for sensitivity, 5.26% (95% CI 0.01–0.26) for specificity, a predictive value of 47.06% (95% CI 0.29–0.65) for a positive response, a predictive value of 50% (95% CI 0.01–0.98) for a negative response, with an overall calculated predictive accuracy of 47.22% (95% CI 0.30–0.64).

[†]Andrew R. Mackay and Marco Clementi shared last authors.

*Correspondence: stefano.guadagni@univaq.it

¹ Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, 67100 L'Aquila, Italy

Full list of author information is available at the end of the article



Conclusions: This is the first reported estimation of predictive accuracy derived from combining chemosensitivity and tumor gene expression analyses on liquid biopsy-derived CTCs, transiently cultured in vitro which, despite limitations, represents a baseline and benchmark which we envisage will be improved upon by methodological and technological advances and future clinical trials.

Keywords: Predictive accuracy, Precision oncology, Liquid biopsies, Circulating tumor cells, Chemosensitivity tests, Tumor gene expression analyses, Recurrent rectal cancer, Colorectal cancer liver metastases, Intraarterial chemotherapy, Targeted therapy

Background

Clinical and biological prognostic markers identify patients with differing risks of a specific outcome regardless of treatment, such as progression or death [1], and can select individuals at high risk of relapse, as potential candidates for alternative treatments. In contrast, predictive markers are associated with response (benefit) or lack of response to a particular therapy relative to other available therapies and identify patients more likely to benefit from a particular treatment [2]. Within this context, tissue and liquid biopsy precision oncology holds great promise in improving therapeutic outcomes, as both represent important methods for detecting prognostic and predictive markers, with additional potential to identify therapeutic targets. This is particularly true for less invasive, serially repeatable liquid biopsies, which are potentially more relevant to disseminated disease.

Tissue biopsies, in accordance with American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) recommendations [3], can be used to detect oncogenic mutations, oncogene overexpression and to evaluate chemosensitivity [4]. Liquid biopsies (blood, ascites, urine, pleural effusion, or cerebrospinal fluid) can be used to do the same but also permit purification and analysis of tumour-derived components including circulating tumor cells (CTCs), exosomes, circulating tumor DNAs (ctDNA), microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and proteins [5, 6], with enhanced potential for identifying prognostic markers, predictive markers and therapeutic targets.

When compared to tumor-derived non-cellular components, intact CTCs not only provide a valuable source of quality tumour cell-derived nucleic acids and proteins for immunocytological, fluorescence in situ hybridization (FISH), DNA sequence, PCR, RT-PCR and multiplex RNA analysis but also the opportunity for transient in vitro culture, enabling chemosensitivity and tumor gene expression analysis to be performed on the same CTC population. Up to 2010, CTC detection and purification methodologies were based upon either biophysical (i.e. Biocoll/Ficoll[®], Oncoquick[®] or Screen-Cell[®] Cyto IS - Sarcelles, France) or antigenic (i.e. CellSearch[®]

system - Menarini Silicon Biosystems) properties. Following 2010, progress in microfluidic-based technologies, devices and principles have resulted in the use of novel antibody-based marker-dependent platforms, physical characteristic-based platforms, and secretome and transcriptome-based platforms, the latter of which, however, involves CTC lysis, eliminating the possibility of CTC culture for drug screening.

The FDA has approved liquid biopsy [7] and has validated the CellSearchTM system (Veridex LCC, Raritan, NJ, USA) as a diagnostic tool for CTC identification and enumeration in a variety of tumours, including colorectal cancer (CRC) and currently holds a dominant position amongst competitors [8]. This system is employed to detect CD45 (Cluster of differentiation 45) negative, EpCAM (Epithelial adhesion molecule) and cytokeratins CK8/18/19 positive CTCs, using anti human CK8/18/19/20 antibodies conjugated with ferrous beads for magnetic purification [8]. Cytokeratins and particularly CK20, are well-established markers of epithelial cell and metastatic CRC CTCs [9] and are employed also for semi-quantitative qRT-PCR analyses [10] and the majority of studies using this system report CTC enumeration as a prognostic marker for progression free survival (PFS) and overall survival (OS) [11]. Drawbacks with this approach, however, include potential CTC underestimation due to epithelial to mesenchymal transition (EMT) and loss of epithelial marker expression, technical bottlenecks and cost, which reduce routine use [8]. Alternative isolation and analytical methods and techniques have also been reported that overcome some of these problems (i.e. leukapheresis and Hydro-Seq technology) [8] and flow cytometry has also been reported to detect CTCs with high sensitivity and specificity [12].

To date, few papers have investigated the therapeutic predictive potential of CTC isolation and enumeration in CRC patients [13–16] or the promise of combining molecular profiling with chemosensitivity analysis, considered for some time to be the best way to improve disease characterisation and selection of individualised therapy [17, 18]. Within this context, patients presenting with unresectable recurrent rectal cancer (RRC) or unresectable CRC liver metastases, refractory to at

least two lines of standard systemic chemotherapy, targeted and radiation therapy, represent good potential candidates for determining the predictive accuracy of combined in vitro (ex-vivo) CTC chemosensitivity and gene expression analysis.

CRC is currently the third most common cancer type, with upwards of ≈ 1.8 million new cases and $\approx 9\%$ of all cancer-related deaths reported annually worldwide [19]. Treatment strategies depend upon disease stage, patient condition, molecular mechanisms, economic parameters, health care systems and unexpected factors, such as the current Sars-Covid-2 pandemic. In highly developed countries, 5-year survival rates for localized CRC of $\approx 90\%$ plummet to $\approx 14\%$ for metastatic or relapsed disease. For stage IV metastatic or recurrent CRC, devoid of known cancer driving mutations or targetable biomarkers ($\approx 85\%$ of patients), current systemic therapeutic regimes include: FOLFOX (leucovorin plus 5-fluorouracil plus oxaliplatin), CAPEOX (capecitabine plus oxaliplatin), FOLFIRI (leucovorin plus 5-fluorouracil plus irinotecan), FOLFIRI (leucovorin plus 5-fluorouracil plus oxaliplatin plus irinotecan), typically combined with bevacizumab or cetuximab or aflibercept and recently new oral drugs such as regorafenib and trifluridine/tipiracil [18, 20–28]. Patients with dominant liver metastatic disease or limited extrahepatic disease, may receive liver-directed intraarterial therapies such as hepatic arterial chemotherapy infusion, chemoembolization [20] and radioembolization to improve local tumor response and to reduce systemic side effects [18]. For all of these patients, liquid biopsy-derived CTCs deserve thorough investigation as a potential source of important predictive information with respect chemosensitivity and chemoresistance, enhancing the possibility of identifying novel alternative therapeutic strategies and reducing toxicity.

For stage IV metastatic or recurrent CRCs refractory to standard systemic therapies, that exhibit detectable overexpression or mutation of known driver oncogenes ($\approx 4\text{--}15\%$), precision oncotherapy represents a viable therapeutic option, in conditions of: i) deficient mismatch repair protein expression (dMMR) and/or DNA microsatellite instability (MSI-H/high), treatable with pembrolizumab and nivolumab or a combination of nivolumab and ipilimumab check-point inhibitors in first and subsequent lines of treatment; ii) specific BRAF^{V600E} mutation treatable with a combination of encorafenib and cetuximab in second or third lines; iii) EGFR overexpression treatable with cetuximab and panitumumab; iv) HER-2 3+ overexpression or HER2 FISH/ISH amplification treatable with trastuzumab, lapatinib, tucatinib and deruxtecan/trastuzumab; v) neurotrophic tropomyosin

receptor kinases (NTRKs) overexpression or expression of novel NTRK chimeric fusions treatable with larotrectinib or entrectinib [21–28].

Within this context, we report a retrospective study of the accuracy of in vitro ex vivo CTC chemosensitivity and tumour gene expression analyses in predicting response to treatment in CRC patients presenting with unresectable refractory RRC or unresectable refractory CRC liver metastases. In this setting, chemotherapeutic agents and monoclonal antibodies used for the multidisciplinary treatment of patients with refractory CRC, were chosen from chemosensitivity assays performed on transiently in vitro cultured liquid biopsy-derived CTCs and from the ratio of tumor gene expression exhibited by the same CTC populations compared to purified peripheral blood mononuclear cells from the same patient.

Methods

Patients

This study involved patients with unresectable and predictable disease course and was approved by ASL n.1 Ethics committee, Abruzzo, Italy (Chairperson: G. Piccioli; protocol number 10/CE/2018; approved: 19 July 2018 (n.1419)). Drug selection, clinical treatments and evaluations were performed at the University of L'Aquila, L'Aquila, Italy. CTC isolation, culture, gene expression and chemosensitivity analyses were performed at the Research Genetic Cancer Centre, Florina, Greece. All patients provided written consent and received complete information about their disease and the implications of the proposed conventional treatment, in accordance with the Helsinki Declaration and the University of L'Aquila committee on human experimentation.

From a cohort of 168 CRC patients, enrolled from 2007 to 2019, comprising 62 patients with unresectable recurrent rectal cancer in progression following two lines of systemic chemotherapy and radiotherapy and 106 patients with unresectable CRC liver metastases in progression after two lines of systemic chemotherapy, 36 patients were retrospectively selected based on the following criteria: submission for precision oncotherapy by combined intraarterial chemotherapy and systemic venous targeted therapy, using drugs selected by comparative chemosensitivity and gene expression analyses performed on in vitro cultured CTCs and PBMCs from the same patient. To ensure the stability and consistency of sample collection and detection, only patients submitted for combined locoregional intraarterial chemotherapy and systemic venous targeted-therapy, whose CTCs had been purified using the same methodology, were included in this retrospective study, whereas patients submitted for systemic venous chemotherapy and/or systemic targeted therapy, and those in which CTC isolation

and culture had been performed with more recent techniques and methodologies, not available at the beginning of the study, were excluded.

Decisions concerning unresectability and precision oncotherapy were made by experienced surgeons, oncologists and radiologists during multidisciplinary meetings. Inclusion criteria were: i) histologically confirmed colorectal cancer diagnosis and complete primary tumor resection; ii) failure of two lines of systemic chemotherapy; iii) Eastern Cooperative Oncology Group (ECOG) performance status of < 4; iv) adequate liver or renal dysfunction (total bilirubin serum levels < 3 mg/dL, serum albumin level > 20 g/L, serum creatinine level < 2 mg/dL). In all cases, systemic chemotherapy ceased 4 weeks prior to the 1st cycle of tailored intraarterial chemotherapy in association with targeted therapy. Patients with inadequate medical records were excluded from this study. Demographic and clinical characteristics of the 36 patients are presented in Table 1.

Liquid biopsy, CTC gene expression and chemosensitivity assays

Sample collection, storage and transportation

Liquid biopsies (≥ 20 mL venous blood) were collected from each patient in sterile 50 mL Falcon tubes, containing 7 mL of 0.02 M ethylenediaminetetraacetic acid (EDTA) anticoagulant (E0511.0250, Duchefa Biochemie B.V., Haarlem, The Netherlands), transported in impact-resistant containers, under refrigeration at 2–8 °C, and analysed within 80 hours [29].

CTC isolation

For CTC isolation, blood samples were layered over 4 mL polysucrose solution (Biocoll 1077, Biochrom, Berlin, Germany) and centrifuged for 20 min at 2500 × g. Peripheral blood mononuclear cells (PBMCs) and CTCs (the buffy coat) were collected and washed with phosphate-buffered saline (PBS, P3813, Sigma-Aldrich, Germany). Cell pellets were resuspended for 10 min in erythrocyte lysis buffer [154 mM NH_4Cl (31,107, Sigma-Aldrich, Germany), 10 mM KHCO_3 (4854, Merck, Germany) and 0.1 mM EDTA]. Cells were then collected by centrifugation, washed in PBS, and incubated with mouse monoclonal anti-human CD45 antibody-conjugated magnetic beads (39-CD45–250, Gentaur, Belgium) for 30 min at 4 °C. Anti CD45 bead-bound cells were collected in a magnetic field and saved for use as non-cancer control PBMCs in qRT-PCR gene expression analyses. Remaining cells were incubated with mouse monoclonal Anti-Pan cytokeratin-conjugated microbeads (PCK/CK4, CK5, CK6, CK8, CK10, CK13 and CK18) (MA1081-M, Gentaur, Belgium) for 30 min at 4 °C and PCK bead-bound cells (CTCs) collected in a magnetic field and washed in

Table 1 Patient demographic and clinical characteristics

| | Median; [IQR] | Number | (%) |
|---|-------------------|--------|--------|
| Age (years) | 60.5; [55.5–67.5] | | |
| - < 75 | | 35 | (97.2) |
| - ≥ 75 | | 1 | (2.8) |
| Gender | | | |
| - M | | 22 | (61.1) |
| - F | | 14 | (38.9) |
| Site of recurrence/metastases | | | |
| - Pelvis | | 27 | (75) |
| - Liver | | 9 | (25) |
| Presence of other metastases | | | |
| - Yes | | 18 | (50) |
| - No | | 18 | (50) |
| Number of previous systemic chemotherapy lines | | | |
| - 2 | | 35 | (97.2) |
| - > 2 | | 1 | (2.8) |
| KRAS, NRAS, BRAF genotype status | | | |
| - KRAS exon 2 codon 12 | | 3 | (8.3) |
| - NRAS mutations | | 0 | (0) |
| - BRAF mutations | | 0 | (0) |
| - Unknown | | 13 | (36.1) |
| SBTT (months) | 16.0; [12–20.5] | | |
| ECOG | | | |
| - 0 | | 0 | (0) |
| - 1 | | 9 | (25) |
| - 2 | | 13 | (36.1) |
| - 3 | | 14 | (38.9) |
| - 4 | | 0 | (0) |
| PFSTT (months) | 7.5; [5–12.5] | | |
| OSTT (months) | 34.0; [23.5–41.5] | | |

IQR Interquartile range, *SBTT* Survival from recurrence/metastases date and first treatment of tailored intraarterial chemotherapy in association with targeted therapy, *ECOG* Eastern Cooperative Oncology Group performance status before first treatment of tailored intraarterial chemotherapy in association with targeted therapy, *PFSTT* Progression free survival after tailored therapy, *OSTT* Overall survival after tailored therapy, *KRAS* Kirsten rat sarcoma virus gene, *NRAS* Neuroblastoma RAS gene, *BRAF* v-Raf murine sarcoma viral oncogene homolog B

PBS. Isolated viable CTCs (IV-CTCs) were counted, and samples containing ≥ 5 viable CTCs per ml of blood were cultured for 6 days in order to obtain sufficient cell numbers for gene expression and chemosensitivity assays.

CTC culture

Purified pan-cytokeratin positive/CD45-negative bead-bound cells were cultured in RPMI-1640 (R0883, Sigma-Aldrich, Germany) containing 10% Fetal Bovine Serum-FBS (F4135, Sigma-Aldrich, Germany) and 2 mmol/l glutamine (G5792; Sigma), in 12-well cell culture plates (Corning, Merck, Germany), without

antibiotics, at 37 °C, 5% CO₂, and culture medium was changed every 2 days, as previously described [30].

CTC validation post-culture

CTC validation was confirmed by positive CK18, CK19, and negative CD45, CD31, N-Cadherin qRT-PCR (see section 2.2.5 for methodology) and by positive Pan-Cytokeratin-APC, and EpCAM-FITC, and negative CD45-PE Immunofluorescence (IF), in 6-day CTC cultures (Fig. 1). Briefly for IF, purified CTCs and PBMCs from the same patient were initially stained with anti-human CD45-PE (phycoerythrin) conjugated mouse monoclonal antibody (304,008, Biolegend, CA, USA) and anti-human EpCAM-FITC (fluorescein isothiocyanate) conjugated mouse monoclonal antibody (324,204, Biolegend, CA, USA), at recommended dilutions, and subsequently, cells were stained with anti-human Pan-Cytokeratin-APC (allophycocyanin, ab201807, Cambridge, UK) conjugated mouse monoclonal antibody (SAB4700666, Sigma-Aldrich, MO, USA), using Leucoperm staining protocol (BUF09C, Bio-Rad, CA, USA). Nuclei were counterstained with DAPI (4',6-diamidino-2-phenylindole, Abbott Molecular, Illinois, USA) and cells were visualised under a Nikon Eclipse 50i microscope, armed with Cytovision software (Leica Biosystems, United States).

CTC gene expression

For gene expression analysis, RNAs were purified from CTC cultures and from corresponding PBMCs using RNeasy Mini Kits, as directed by the manufacturer (74,105, Qiagen, Hilden, Germany). RNAs (1 µg) were reverse transcribed using a PrimeScript RT Reagent Kit, as directed by the manufacturer (RR037A, Takara, Beijing, China) and subjected to KAPA SYBR Fast Master Mix (2×) Universal (KK4618, KAPA Biosystems, MA, USA) real-time qPCR, in a final volume of 20 µl. Real-time qRT-PCR reactions were performed in a final volume of 20 µl and characterised by 2 min denaturation at 95 °C, followed by 40 cycles consisting of 10 sec denaturation at 95 °C and 30 sec annealing at 59 °C. Melting-curve analysis was performed from 70 °C to 90 °C, with 0.5 °C increments of 5 s, at each step. Reactions were employed to evaluate the expression of multidrug resistance gene-ABCB1 (MDR1), thymidylate synthase (TYMS), dihydrofolate reductase (DHFR), DNA excision repair protein (ERCC1), glutathione S-transferase (GST), epidermal growth factor (EGF), vascular epidermal growth factor (VEGF), 18S ribosomal RNA (18S rRNA), β actin (ACTB), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), the specific primers for which have been previously reported [31]. All reactions were performed in triplicate, compared to template-free negative controls,

and analysed by Livak relative quantification [32]. Gene expression was quantified using the following equations:

$$\Delta Ct_{(\text{threshold Cycle})} = Ct_{\text{target}} - Ct_{\beta\text{-actin}}$$

$$\Delta\Delta Ct = \Delta Ct_{(\text{treated CTCs})} - \Delta Ct_{(\text{non-cancer cells})}$$

$$\text{Relative expression level} = 2^{-\Delta\Delta Ct}$$

$$\% \text{Gene expression} = 100 \times (2^{-\Delta\Delta Ct} - 1)$$


and classified as low (<50%) or high (>50%) overexpression, as previously described [31].

CTC chemosensitivity

For chemosensitivity assays, 6 day CTC cultures in 12-well plates were treated with the following drug concentrations: 1 µM alkeran (M2011, Sigma-Aldrich, Germany), 1 µM doxorubicin (D1515, Sigma-Aldrich, Germany), 1 µM cisplatin (P4394, Sigma-Aldrich, Germany), 10 µM 5-fluorouracil (F6627, Sigma-Aldrich, Germany), 1.12 µM oxaliplatin (O9512, Sigma-Aldrich, Germany), 1 µM carboplatin (41575-94-4, Sigma-Aldrich, Germany), 5 µM irinotecan (I1406, Sigma-Aldrich, Germany), 1 µM raltitrexed (112887-68-0, Sigma-Aldrich, Germany) and 2 µM mitomycin C (M4287, Sigma-Aldrich, Germany), in complete culture medium. Cell viability was assessed by Annexin V-PE (559,763; BD Bioscience, USA) flow cytometry (BD Instruments Inc., San José, CA, USA), and the percentage of living, dead and dying cells evaluated using BD Cell-Quest Software (BD Instruments Inc., USA (Fig. 2). Controls included untreated cells incubated in the presence and absence of chemotherapeutic drugs and cell-free counterparts. The percentage of non-viable CTCs was calculated under non-drug and drug-treated conditions, and chemosensitivity was classified as either: i) non-sensitive <35% death; ii) partially sensitive 35–80% death, or iii) highly sensitive >80% death.

Precision oncology protocol criteria

Decisions concerning precision oncology were made by experienced oncologists, surgeons and radiologists during multidisciplinary meetings based on gene expression and chemosensitivity analyses, previous systemic chemotherapeutic protocols, and in vitro drug cytotoxicity under hypoxic conditions [33]. For intraarterial chemotherapy, drug regimens were selected according to the



following criteria: i) mono-chemotherapy for CTCs with high sensitivity (> 80% of dead and dying cells) for one or more drug, with highest chemosensitivity indicating the

drug to be used, ii) poly-chemotherapy for CTCs exhibiting partial sensitivity, and iii) with respect to drug activity under conditions of hypoxia. For targeted therapy, the




Fig. 2 Representative flow cytometric analyses, with corresponding tables, showing the percentage changes in live, dead, late apoptotic and apoptotic Annexin-V positive CTCs, in 72 hour-chemosensitivity assays of cultured CTCs from the same individual (Case 1), demonstrating chemosensitivity to Mitomycin-C (MMC, 2 μM) (A) but not Flurouracil (5-FU, 10 μM) (B), compared to respective untreated CTC controls

presence/absence of KRAS and NRAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61) and/or exon 4 (codons 117 and 146) was verified, and subsequent drug selection was based upon existing therapeutic options already recommended by evolving international guidelines for clinical practice, and high CTC: PBMC gene over-expression ratios, with the highest percentage used to select each drug. Specifically, for EGFR overexpression cetuximab was selected and for high VEGFR overexpression bevacizumab was selected. If CTC: PBMC expression ratios were $>50\%$, target-therapy selection was based upon the highest ratio of tumour gene overexpression.

Intraarterial chemotherapy techniques

Intraarterial chemotherapeutic procedures for unresectable refractory RRC and for unresectable refractory CRC liver metastases, together with eligibility criteria, have been described previously [17, 18]. For pelvic recurrences, hypoxic pelvic perfusion (HPP) requires specialized surgical skill and can also be performed percutaneously [34], whereas regional intraarterial chemotherapy for CRC liver metastases requires an interventional radiologist [18, 35]. Both procedures included hemofiltration to reduce toxicity [17, 18].

Response and adverse events criteria

Responses, assessed by computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET), were evaluated 3 months following the first cycle of intraarterial chemotherapy combined with targeted therapy and classified using Response Evaluation Criteria in Solid Tumors (version 1.1), as either complete responses (CR), partial responses (PR), corresponding to a minimum 30% reduction in tumour volume, stable disease (SD) or progressive disease (PD) [36]. Patient responses prior to 2009 were re-classified retrospectively. Adverse reactions were evaluated using National Cancer Institute-Common Terminology Criteria for Adverse Events software (version 4.03) and classified from 0 to 4.

Statistical analyses

Due to the low sample size and plausible deviations from distributional symmetry, patient demographic and clinical characteristics are summarized as percentages and median values. Cut-off values for chemosensitivity tests and tumor gene expression analyses were calculated from combined optima of positive predictive values. Specifically, this pair of cut-off values was derived from the pair of thresholds that maximized predictive accuracy, considering all possible confusion matrices. Binomial exact confidence intervals of 95% are provided for sensitivity,

specificity, positive predictive, negative predictive and accuracy values.

Results

CTC chemosensitivity and gene expression analyses, used for selecting precision oncotherapy protocols, and patient therapeutic responses

With respect to CTC purification, the CTC detection rate in this cohort of advanced stage metastatic CRC patients was 100%, the mean (\pm s.e.) number of purified CTCs per millilitre of blood was 10.3 ± 0.35 (range 6.2 to 16.3) (Table 2). For 25 mls blood samples this translated into total numbers of CTCs per patient ranging from ≈ 150 to 400, which was expanded by 6-day in vitro culture to between $\approx 35,000$ to 100,000 CTCs per patient for the gene expression and chemosensitivity assays used to select locoregional chemotherapy and systemic targeted therapy protocols.

RECIST 1.1 responses to combined intraarterial chemotherapy and targeted therapy, selected by CTC chemosensitivity and gene expression assays, and the KRAS mutational status of tumors are presented in Tables 2 and 3.

Response predictive accuracy of precision oncotherapy protocols, selected by chemosensitivity and gene expression analyses performed on in vitro cultured liquid biopsy-derived CTCs and PBMCs

With respect to the 36 patients assessed in this study, intraarterial chemotherapy combined with targeted therapy elicited 17 partial responses (PR), 18 stable disease (SD) responses and 1 progressive disease (PD) response. RECIST 1.1 responses subdivided into positive (CR + PR) and negative (SD + PD) responses, in relation to CTCs chemosensitivity and tumor gene expression tests for targeted therapy, are presented in Table 4. Tests were defined as positive when $\geq 70\%$ of drug-treated CTCs were killed and CTC: PBMC tumor gene expression ratios were $\geq 50\%$. Tests were defined as negative when $< 70\%$ of drug-treated CTCs were killed and CTC: PBMC tumor gene expression ratios were $< 50\%$.

Considering both types of therapy (intraarterial and targeted) and associated respective cut-offs for assay positivity, we report 16 true positive responses (TP), 1 false positive response (FP), 18 true negative responses (TN) and 1 false negative response (FN), which translate into a sensitivity of 94.12% (16/17) (95% CI 0.71–0.99), specificity of 5.26% (1/19) (95% CI 0.01–0.26), a positive predictive value of 47.06% (16/34) (95% CI 0.29–0.65), a negative predictive value of 50% (1/2) (95% CI 0.01–0.98) and an over-all predictive accuracy of 47.22% (17/36) (95% CI 0.30–0.64).

Table 2 Protocols of intraarterial chemotherapy based on CTC chemosensitivity, and RECIST 1.1 responses

| Pt | IV-CTCs | Intraarterial chemotherapy protocols | | | Response in association with targeted therapy |
|-----|---------|--------------------------------------|------------------------|-----------------------|---|
| | | Drug | % CTC chemosensitivity | Dose administered | |
| 1R | 12.2/ml | MMC | 82 | 25 mg/m ² | PR |
| 2R | 16.2/ml | 5-FU | 70 | 100 mg/m ² | PR |
| | | OX | 72 | 80 mg/m ² | |
| 3R | 8.4/ml | MMC | 80 | 25 mg/m ² | PR |
| | | OX | 75 | 80 mg/m ² | |
| | | RAL | 70 | 3 mg/m ² | |
| 4R | 12.2/ml | MMC | 70 | 25 mg/m ² | PR |
| | | CIS | 70 | 70 mg/m ² | |
| | | RAL | 70 | 3 mg/m ² | |
| 5R | 7.5/ml | MMC | 80 | 25 mg/m ² | PR |
| | | RAL | 70 | 3 mg/m ² | |
| 6R | 6.9/ml | MMC | 80 | 25 mg/m ² | PR |
| | | RAL | 75 | 3 mg/m ² | |
| 7R | 15.1/ml | ALK | 70 | 30 mg/m ² | PR |
| | | CAR | 75 | 100 mg/m ² | |
| 8R | 16.3/ml | ALK | 75 | 30 mg/m ² | PR |
| | | CAR | 75 | 100 mg/m ² | |
| 9R | 8.9/ml | OX | 70 | 80 mg/m ² | PR |
| 10R | 10/ml | OX | 70 | 80 mg/m ² | PR |
| | | MMC | 75 | 25 mg/m ² | |
| 11R | 9.5/ml | OX | 70 | 80 mg/m ² | PR |
| | | MMC | 75 | 25 mg/m ² | |
| 12R | 8.9/ml | OX | 75 | 80 mg/m ² | PR |
| | | MMC | 75 | 25 mg/m ² | |
| 13R | 7.5/ml | MMC | 80 | 25 mg/m ² | PR |
| 14R | 8.9/ml | MMC | 82 | 25 mg/m ² | PR |
| 15R | 6.9/ml | MMC | 75 | 25 mg/m ² | PR |
| 16R | 12.2/ml | MMC | 82 | 30 mg/m ² | PR |
| 17R | 16.2/ml | 5-FU | 60 | 600 mg/m ² | PR |
| | | OX | 72 | 150 mg/m ² | |
| 18R | 7.5/ml | OX | 75 | 80 mg/m ² | SD |
| | | IRI | 80 | 100 mg/m ² | |
| 19R | 9/ml | MMC | 85 | 25 mg/m ² | SD |
| 20R | 8.4/ml | OX | 85 | 80 mg/m ² | SD |
| 21R | 9.7/ml | MMC | 83 | 25 mg/m ² | SD |
| 22R | 6.9/ml | MMC | 80 | 25 mg/m ² | SD |
| 23R | 9.8/ml | MMC | 75 | 25 mg/m ² | SD |
| 24R | 16.2/ml | DOX | 72 | 35 mg/m ² | SD |
| | | OX | 65 | 80 mg/m ² | |
| 25R | 9.8/ml | MMC | 70 | 25 mg/m ² | SD |
| | | RAL | 70 | 3 mg/m ² | |
| 26R | 8.9/ml | MMC | 80 | 25 mg/m ² | SD |
| 27R | 6.9/ml | MMC | 80 | 25 mg/m ² | SD |
| 28L | 9.4/ml | MMC | 85 | 25 mg/m ² | SD |
| 29L | 16.2/ml | MMC | 80 | 25 mg/m ² | SD |
| 30L | 7.5/ml | OX | 75 | 150 mg/m ² | SD |
| | | IRI | 80 | 200 mg/m ² | |

Table 2 (continued)

| Pt | IV-CTCs | Intraarterial chemotherapy protocols | | | Response in association with targeted therapy |
|------|---------|--------------------------------------|------------------------|-----------------------|---|
| | | Drug | % CTC chemosensitivity | Dose administered | |
| 31 L | 10/ml | IRI | 90 | 200 mg/m ² | SD |
| 32 L | 16.2/ml | IRI | 80 | 200 mg/m ² | SD |
| 33 L | 7.5/ml | MMC | 81 | 30 mg/m ² | SD |
| 34 L | 9.8/ml | MMC | 70 | 30 mg/m ² | SD |
| 35 L | 9.9/ml | MMC | 75 | 30 mg/m ² | SD |
| | | OX | 70 | 150 mg/m ² | |
| 36 L | 6.9/ml | MMC | 80 | 30 mg/m ² | PD |

Pt Patient, R Patient with unresectable refractory recurrent rectal cancer, L Patient with unresectable refractory colo-rectal cancer liver metastases, IV-CTCs Isolated viable circulating tumor cells in patient blood prior to culture, 5-FU 5 fluorouracil, MMC Mitomycin, IRI Irinotecan, OX Oxaliplatin, RAL Raltitrexed, DOX Doxorubicin, ALK Alkeran, CIS Cisplatin, CAR Carboplatin, PR Partial response, SD stable disease, PD Progressive disease

Adverse events

No technical, hemodynamic or vascular complications were observed during HPP and HAI procedures, no perfusion-related postoperative deaths were registered, and all adverse events are reported in Table 5.

Discussion

Interest in precision oncology has grown dramatically over the past 20 years and routine characterisation of oncogenic pathways activated in primary, recurrent and metastatic tumour tissue biopsies form the mainstay of precision oncology selection of individualised therapeutic strategies, which has led to improvements in survival rates. Tissue biopsy procedures, however, are invasive, can facilitate tumour dissemination and are of limited use in patient follow-up. These drawbacks have stimulated interest into the potential use of liquid biopsies, as a source of tumour-derived components including CTCs that can be enumerated as a prognostic marker, purified and characterised at the biomolecular and chemosensitivity levels to provide predictive information for precision oncology.

Although current clinical use of liquid biopsies remains limited, CTCs have been isolated from patients with a variety of tumour types [37, 38], including CRC [17, 18]. CTC research has evolved from prognostic studies based upon CTC enumeration, to predictive clinical response studies based upon the *in vitro* chemosensitivity and tumor gene expression profiles of cultured CTCs. Various methods for CTC isolation and enumeration have been reported [10], although FDA approval of a particular method and equipment has led to a commanding position [8]. Furthermore, in addition to liquid biopsy-derived CTC purification methodologies, a variety of methods have been reported for subsequent CTC *in vitro*

cultivation in order to facilitate chemosensitivity and tumor gene expression analysis [12, 39].

A potential drawback of current methodologies, however, is the exclusive use of epithelial markers for detecting and purifying CTCs that may miss CTCs that have undergone epithelial to mesenchymal transition (EMT). EMT is a pre-requisite for metastatic dissemination in majority of carcinomas, is characterised by a shift to SNAIL, ZEB and TWIST transcriptional activity, TGF β and Wnt signaling and matrix metalloproteinase activity and results in repression of epithelial marker expression and “metaplastic” conversion to a motile mesenchymal phenotype [10]. CTCs numbers may, therefore, be underestimated by methods that exclusively employ epithelial markers. Furthermore, purified epithelial CTCs may differ to mesenchymal CTCs in biomolecular profiles and chemosensitivity, potentially making information from CTC analysis incomplete, more relevant to epithelial rather than mesenchymal tumour components and may differ to information gained from tissue biopsies, leading to differences in precision oncology predictions of clinical efficacy between liquid and tissue biopsies.

Given these variables and considerations, the salient question remains whether it is possible to provide a calculated prediction of clinical response to select tailored drugs using a specific CTC methodology, and would this alter if the tumour type, patient population or analytical methodology changes?

The predictive accuracy of precision oncology depends initially upon patient characteristics, tumor type and stage. Here, we evaluated the predictive accuracy of precision oncology on a specific population of CRC patients, refractory to at least two standard lines of systemic therapy, undoubtedly more chemo-resistant than patients with unresectable recurrent rectal cancer or unresectable CRC liver metastases submitted to

Table 3 Targeted therapy protocols selected according to CTC: PMBC percentage gene overexpression ratios, and associated RECIST 1.1 responses

| Pt | EGFR % | VEGFR % | MDR1% | TYMS % | DHFR % | ERCC1% | GST % | Protocol of targeted therapy | Response in association with intraarterial chemotherapy |
|------|--------|---------|-------|--------|--------|--------|-------|------------------------------|---|
| 1R | 45 | 70 | 80 | 0 | 0 | 0 | 18 | BEV | PR |
| 2R | 45 | 70 | 80 | 0 | 0 | 0 | 10 | BEV | PR |
| 3R | 50 | 65 | 65 | 0 | 0 | 0 | 10 | BEV | PR |
| 4R | 50 | 20 | 55 | 0 | 0 | 0 | 10 | CET | PR |
| 5R | 65 | 50 | 70 | 0 | 0 | 0 | 5 | CET | PR |
| 6R | 50 | 80 | 70 | 0 | 0 | 0 | 10 | BEV | PR |
| 7R | 50 | 20 | 80 | 10 | 0 | 25 | 20 | CET | PR |
| 8R | 50 | 20 | 60 | 0 | 0 | 0 | 10 | CET | PR |
| 9R | 50 | 30 | 65 | 10 | 0 | 0 | 10 | CET | PR |
| 10R | 70 | 60 | 70 | 0 | 0 | 0 | 0 | CET | PR |
| 11R | 60 | 55 | 65 | 5 | 0 | 0 | 10 | CET | PR |
| 12R | 60 | 55 | 65 | 5 | 0 | 0 | 15 | CET | PR |
| 13R | 40 | 70 | 80 | 5 | 10 | 0 | 10 | BEV | PR |
| 14R | 50 | 70 | 70 | 0 | 0 | 0 | 10 | BEV | PR |
| 15R | 50 | 20 | 65 | 0 | 0 | 0 | 15 | CET | PR |
| 16R | 65 | 70 | 80 | 0 | 0 | 0 | 18 | BEV | PR |
| 17R | 55 | 70 | 80 | 0 | 0 | 0 | 10 | BEV | PR |
| 18R | 60 | 85 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
| 19R | 60 | 55 | 60 | 0 | 0 | 0 | 10 | CET | SD |
| 20R | 70 | 45 | 58 | 0 | 0 | 0 | 12 | CET | SD |
| 21R | 10 | 65 | 65 | 0 | 0 | 0 | 20 | BEV | SD |
| 22R | 50 | 80 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
| 23R | 60 | 70 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
| 24R | 80 | 35 | 60 | 0 | 25 | 0 | 0 | CET | SD |
| 25R | 60 | 70 | 70 | 0 | 0 | 0 | 0 | BEV | SD |
| 26R | 40 | 80 | 70 | 5 | 0 | 15 | 15 | BEV | SD |
| 27R | 40 | 60 | 60 | 0 | 0 | 0 | 10 | BEV | SD |
| 28L | 50 | 70 | 70 | 10 | 0 | 0 | 10 | BEV | SD |
| 29L | 40 | 50 | 60 | 0 | 10 | 0 | 10 | BEV | SD |
| 30L | 60 | 85 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
| 31*L | 65 | 80 | 83 | 0 | 0 | 0 | 10 | BEV | SD |
| 32L | 50 | 80 | 60 | 0 | 0 | 0 | 8 | BEV | SD |
| 33L | 60 | 90 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
| 34L | 60 | 30 | 70 | 0 | 0 | 0 | 10 | CET | SD |
| 35*L | 45 | 55 | 70 | 0 | 0 | 0 | 10 | BEV | SD |
| 36*L | 50 | 80 | 70 | 0 | 0 | 0 | 10 | BEV | PD |

CTC Circulating tumor cells, PMBCs Peripheral mononuclear blood cells, Pt Patient, R Patient with unresectable refractory recurrent rectal cancer, L Patient with unresectable refractory colo-rectal cancer liver metastases, EGFR Epidermal growth factor receptor, VEGFR Vascular endothelial growth factor receptor, MDR1 Multidrug resistance gene (ABC1 gene), TYMS Thymidylate synthase gene, DHFR Dihydrofolate reductase, ERCC1 DNA excision repair protein, GST Glutathione S-transferases, BEV Bevacizumab (dosage administered = 5 mg/kg), CET Cetuximab (dosage administered = 250 mg/m²), PR Partial response, SD Stable disease, PD Progressive disease

*KRAS (Kirsten rat sarcoma virus gene) mutated in codon 12, exon 2

first line treatment. The predictive accuracy of precision oncotherapy also depends upon the methodology used for CTC isolation, enrichment, in vitro culture, chemosensitivity, tumor gene expression, etc. In this study, due to the long accrual period, the predictive accuracy of a

particular methodology for CTC purification, culture and analysis, was evaluated. This methodology has now been improved by recent technical advances, which if available during the period of study, may have enhanced predictive accuracy.

Table 4 Positive and negative RECIST 1.1 responses after intraarterial chemotherapy and targeted therapy, using protocols selected by positive or negative CTC chemosensitivity and tumor gene expression analyses

| CTC chemosensitivity assays for intra-arterial chemotherapy and CTC tumor gene expression assays for targeted therapy | RECIST 1.1 Response to intra-arterial chemotherapy and targeted therapy selected by CTC chemosensitivity and tumor gene expression analyses | | |
|---|---|--------------------------------------|-------|
| | Positive patient responses (CR + PR) | Negative patient responses (SD + PD) | Total |
| Positive test [CTC death \geq 70% plus Gene overexpression \geq 50%] | 16 | 18 | 34 |
| Negative test [CTC death <70% plus Gene overexpression <50%] | 1 | 1 | 2 |
| Total | 17 | 19 | 36 |

CTC Circulating tumor cell, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease

Table 5 Adverse events in 27 patients with unresectable refractory RRC and 9 patients with unresectable refractory CRC liver metastases submitted for Hypoxic Pelvic Perfusion (HPP)/targeted therapy or Hepatic Artery Infusion/targeted therapy based on in vitro CTC chemosensitivity and gene expressions analyses

| Adverse events | Grade | HPP/target-therapy, N = 27 | HAI/target therapy, N = 9 | Total, N = 36 |
|--|-------|----------------------------|---------------------------|---------------|
| | | N (%) | N (%) | N (%) |
| Bone marrow hypocellularity | -1/2 | 3 (11) | 1 (11) | 4 (11) |
| | -3/4 | 1 (4) | 0 | 1 (3) |
| Nausea/vomiting | -1/2 | 3 (11) | 1 (11) | 4 (11) |
| | -3/4 | 0 | 1 (11) | 1 (3) |
| Diarrhea | -1/2 | 0 | 1 (11) | 1 (3) |
| | -3/4 | 0 | 0 | 0 |
| Alopecia | -1/2 | 2 (7) | 1 (11) | 3 (8) |
| | -3/4 | 0 | 0 | 0 |
| Fatigue | -1/2 | 2 (7) | 1 (11) | 3 (8) |
| | -3/4 | 0 | 0 | 0 |
| Neuropathy | -1/2 | 2 (7) | 1 (11) | 3 (8) |
| | -3/4 | 0 | 0 | 0 |
| Hand Foot Syndrome | -1/2 | 0 | 1 (11) | 1 (3) |
| | -3/4 | 0 | 0 | 0 |
| Rash | -1/2 | 0 | 2 (22) | 2 (5.5) |
| | -3/4 | 0 | 0 | 0 |
| Non-infectious fever | -1/2 | 0 | 4 (44) | 4 (11) |
| | -3/4 | 0 | 0 | 0 |
| Perineal skin toxicity | -1/2 | 6 (22) | 0 | 6 (16.6) |
| | -3/4 | 5 (18) | 0 | 5 (14) |
| AST and ALT increased | -1/2 | 0 | 1 (11) | 1 (3) |
| | -3/4 | 0 | 0 | 0 |
| Persistent leakage of fluid from the inguinal incision | -1/2 | 3 (11) | 0 | 3 (8) |
| | -3/4 | 1 (4) | 0 | 1 (3) |
| Inguinal hematoma | -1/2 | 1 (4) | 1 (11) | 2 (5.5) |
| | -3/4 | 0 | 0 | 0 |

AST Aspartate transaminase, ALT Alanine transaminase

Based on a predictive accuracy value of 47.2% for the methodology employed, the main clinical message is that patients with unresectable recurrent rectal cancer or unresectable CRC liver metastases, refractory to at

least two lines of traditional systemic therapy, exhibited a positive RECIST 1.1. response in \approx 50% of cases. This represents the first reported estimation of predictive accuracy derived from combined chemosensitivity and

tumor gene expression analysis of in vitro cultured CTCs and extends a recent meta-analysis reporting a predictive value of chemosensitivity assays alone for individualized CRC chemotherapy [40]. Furthermore, the combined positivity cut-off of $\geq 70\%$ cell death for chemosensitivity and $\geq 50\%$ for CTC: PBMC tumor gene expression ratios, were selected considering the positive predictive value, which essentially focus on an optimized RECIST 1.1 response, maximizing predictive accuracy. Choosing pairs of lower cut-off values, potential oncotherapy precision protocols should consider chemotherapeutic agents for which CTCs exhibit greater resistance and/or monoclonal antibodies for less expressed CTC antigens.

The reported predictive accuracy value of 47.2%, is indeed impressive considering that the CTCs from 77.8% of patients exhibited over-expression of the multi-drug resistance gene MDR1 ($\geq 65\%$), CTCs from 19.5% of patients exhibited significant over-expression of ERCC1 and GST ($>15\%$), involved in platinum resistance [41] and CTCs from 22.8% of patients exhibited $\geq 5\%$ over-expression of TYMS or DHFR, involved in 5-fluorouracil resistance [42, 43].

Another important message from this study is that transient in vitro culture of liquid biopsy-derived CTCs can provide sufficient cell numbers for screening anticancer compounds including agents not normally prescribed for any particular tumor type, of relevance for “drug repurposing” [39]. Indeed, 72% of CTCs in the refractory CRC patient group exhibited sensitivity to Mitomycin C, 5.5% exhibited sensitivity to Alkeran and 2.7% exhibited sensitivity to Doxorubicin, agents that are not currently recognized as particularly active against CRC and have been reported to be ≈ 10 times more cytotoxic under hypoxic conditions [33]. In the present study, CTC chemosensitivity assays were not performed under hypoxic conditions, suggesting that the cytotoxic potential of these agents could be further enhanced via intraarterial administration to improve access to hypoxic tumour regions or using therapeutic protocols that promote tissue hypoxia, such as hypoxic pelvic perfusion (HPP), in order to take therapeutic advantage of chronic or transient tumour tissue hypoxia [44].

Limitations of this study, include: i) the small patient sample size, which in any case provided a confidence interval for predictive accuracy of 95% (CI 0.30–0.64); ii) the inclusion of data from CTC populations obtained from patients with recurrent rectal cancer and CRC liver metastases, mitigated somewhat by the need to compare CTCs disseminating from recurrent and overt metastatic sites; iii) transient in vitro CTC culture, used to obtain sufficient numbers for assay, which may have altered gene expression, chemosensitivity and reduced predictive accuracy, deemed necessary for reasons of

methodological homogeneity for this study, initiated 2007 and terminated in 2019, which also explains why novel miniaturized system-based methods were not used; iv) the use of methodology for the evaluation of apoptosis that may have underestimated total death by not measuring paraptosis, ferroptosis and/or necroptosis; and v) lack of novel recent methodological improvements (microfluidic based systems, anti-CK20 antibodies and EMT markers), also for reasons of methodological homogeneity for the duration of this 2007–2019 retrospective study.

Despite these limitations and emphasizing combined treatment with intraarterial chemotherapy and systemic target therapy for advanced CRC patients, refractory to at least two lines of systemic therapy, this study provides interesting biostatistical information for multidisciplinary oncological teams for quantifying the predictive accuracy of the particular CTC-isolation/assay methodology employed. We do not, however, exclude the possibility that predictive accuracy could be improved by recent technological and biomolecular innovations (see above) nor does this study evaluate the relative importance of intraarterial chemotherapy in determining tumor response.

Conclusions

The biomolecular methodology utilised in this retrospective study of patients with unresectable refractory RRC and unresectable refractory CRC liver metastases, provides a predictive accuracy of $\approx 50\%$ for response to liquid biopsy precision oncology-selected intraarterial chemotherapy and targeted therapy. We envisage that this value will be improved by novel technologies and therapeutic agents, and by upgrading methodology to ensure purification of all potentially metastatic epithelial, quasi-mesenchymal and mesenchymal CTC subpopulations, to include physiologically relevant controls in addition to PBMCs, and by eventual methodological standardization. Despite the challenges in applying these procedures to wider populations in non-research settings, the encouraging result of this retrospective study, employing CTC purification procedures relevant to 2007–2019, sets the stage for potential improvements in predictive accuracy in subsequent clinical trials employing current and future technological and methodological improvements.

Abbreviations

FDA: Food and Drug Administration; BRAF: v-Raf murine sarcoma viral oncogene homolog B; CK-20: Cytokeratin-20; EGFR: Epithelial Growth Factor Receptor; EMT: Epithelial-Mesenchymal-Transition; CD45: Cluster of differentiation 45; EpCAM: Epithelial adhesion molecule; pan-CK: Pan-Cytokeratin; qRT-PCR: Reverse Transcriptase quantitative Polymerase Chain Reaction; SNAIL: Gene family of zinc-finger transcription factors; ZEB: Gene family of zinc finger transcription factors; TWIST: Twist gene family; TGF β : Transforming growth factor

β ; Wnt: Wingless and Int – 1 signaling pathway; CT: Computed tomography; MRI: Magnetic resonance imaging; PET: Positron emission tomography; CD31: Platelet endothelial cell adhesion molecule; DAP: 4',6-diamidino-2-phenylindole; EpCAM-FITC: Antibody against Epithelial cell adhesion molecule conjugated to fluorescein isothiocyanate; CD45-PE: Antibody against Cluster of differentiation 45 conjugated to phycoerythrin; Pan-Cytokeratin-APC: Antibody against a panel of cytokeratins conjugated to allophycocyanin; ACTB: β actin; 18S rRNA: 18S ribosomal RNA; 5-FU: 5 fluorouracil; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; MMC: Mitomycin; IRI: Irinotecan; OX: Oxaliplatin; RAL: Raltitrexed; DOX: Doxorubicin; ALK: Alkeran; CIS: Cisplatin; CAR: Carboplatin.

Acknowledgments

None.

Conflict of interest

The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. None of the authors have any COI/ Financial Disclosure.

Authors' contributions

S.G., F.M., A.R.M., P.A., I.P. wrote the main manuscript text. S.G., P.P., A.R.F., prepared figures and Tables. D.S., G.B., C.F., V.G. made data curation. P.A., P.P., made biomolecular analyses. G.S., M.C., G.F., E.R., G.B. made clinical treatments. M.V. supervised statistical analysis. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding

This research received no external funding.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to privacy reasons but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the Ethics Committee of the "Azienda Sanitaria Locale" (ASL) n.1 of the "Regione Abruzzo", Italy (Chairperson: G. Piccioli; protocol number 10/CE/2018; approved: 19 July 2018 (n.1419)). Members of ASL n.1 Ethics committee

| | |
|------------------------|--|
| Gianlorenzo PICCIOLI | Chairperson; Magistrate |
| Claudio FERRI | Clinician |
| Marco Valenti | Biostatistic |
| Domenico PARISE | Substitute of Hospital Health Director |
| Maurizio PAOLONI | Clinician |
| Marco CARMIGNANI | Pharmacologist |
| Elvira D'ALESSANDRO | Geneticist |
| Goffredo DEL ROSSO | Clinician |
| Mario DI PIETRO | Pediatrician |
| Antonio BARILE | Radiologist |
| Roberto BERRETTONI | Medical Devices |
| Ester LIBERATORE | Hospital Pharmacy |
| Patrizia MASCIOVECCHIO | Coroner |
| Fabrizio ANDREASSI | Clinical Engineering |
| Carmine ORLANDI | Nutritionist |
| Luciano LIPPA | Clinician |
| Giovanni MUTTILLI | Nurse |
| Eleonora CORONA | Patient Organization |

| | |
|--------------------|---------------------|
| Carlo DI STANISLAO | Clinical Secretary |
| Marivera DE ROSA | Political Secretary |

Informed consent was obtained from all subjects in the study.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Author details

¹Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, 67100 L'Aquila, Italy. ²Department of Oncology and Hematology, Azienda Ospedaliera "Ospedali Riuniti Marche Nord", Pesaro, Italy. ³Department of Prevention and Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. ⁴Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. ⁵Research Genetic Cancer Centre S.A, Florina, Greece. ⁶Research Genetic Cancer Centre International GmbH, Zug, Switzerland.

Received: 7 February 2022 Accepted: 8 June 2022

Published online: 16 June 2022

References

- Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. *J Clin Oncol*. 2005;23:2020–7.
- McShane LM. Statistical challenges in the development and evaluation of marker-based clinical tests. *BMC Med*. 2012;10:52.
- Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer. Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Arch Pathol Lab Med*. 2017;141:625–57.
- Yoon YS, Kim JC. Recent applications of chemosensitivity tests for colorectal cancer treatment. *World J Gastroenterol*. 2014;20:16398–408.
- Fernández-Lázaro D, García Hernández JL, García AC, Córdova Martínez A, Mielgo-Ayuso J, Cruz-Hernández JJ. Liquid biopsy as novel tool in precision medicine: origins, properties, identification and clinical perspective of cancer's biomarkers. *Diagnostics*. 2020;10:215.
- Wong C-H, Chen Y-C. Clinical significance of exosomes as potential biomarkers in cancer. *World J Clin Cases*. 2019;7:171–90.
- Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R. Real-time liquid biopsies become a reality in cancer treatment. *Ann Transl Med*. 2015;3:36.
- Ding Y, Li W, Wang K, Xu C, Hao M, Ding L. Perspectives of the application of liquid biopsy in colorectal cancer. *Biomed Res Int*. 2020;6843180. <https://doi.org/10.1155/2020/6843180>.
- Welinder C, Jansson B, Lindell G, Wenner J. Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. *Cancer Lett*. 2015;358:43–6. <https://doi.org/10.1016/j.canlet.2014.12.024>.
- Hendricks A, Brandt B, Geisen R, Dall K, Röder C, Schafmayer C, et al. Isolation and enumeration of CTC in colorectal Cancer patients: introduction of a novel cell imaging approach and comparison to cellular and molecular detection techniques. *Cancers*. 2020;12:2643. <https://doi.org/10.3390/cancers12092643>.
- Vacante M, Ciuni R, Basile F, Biondi A. The liquid biopsy in the Management of Colorectal Cancer: an overview. *Biomedicines*. 2020;8:308. <https://doi.org/10.3390/biomedicines8090308>.
- Papasotiriou I, Chatziioannou M, Pessiou K, Retsas I, Dafouli G, Kyriazopoulou A, et al. Detection of circulating tumor cells in patients with breast, prostate, pancreatic, Colon and Melanoma Cancer: a blinded comparative study using healthy donors. *J C T*. 2015;6:543–53. <https://doi.org/10.4236/jct.2015.67059>.

13. Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, et al. Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. *Ann Surg*. 2015;261:164–71.
14. Arrazubi V, Mata E, Antelo ML, Tarifa A, Herrera J, Zazpe C, et al. Circulating tumor cells in patients undergoing resection of colorectal cancer liver metastases. Clinical utility for long-term outcome: a prospective trial. *Ann Surg Oncol*. 2019;26:2805–11.
15. Wang L, Zhou S, Zhang W, Wang J, Wang M, Hu X, et al. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients. *Int J Color Dis*. 2019;34:589–97.
16. Musella V, Pietrantonio F, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, et al. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. *Int J Cancer*. 2015;137:1467–74.
17. Guadagni S, Fiorentini G, De Simone M, Masedu F, Zoras O, Mackay AR, et al. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study. *J Cancer Res Clin Oncol*. 2020;146:205–19. <https://doi.org/10.1007/s00432-019-03046-3>.
18. Guadagni S, Clementi M, Mackay AR, Ricevuto E, Fiorentini G, Sarti D, et al. Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy. Observational cohort study. *J Cancer Res Clin Oncol*. 2020;146:1273–90.
19. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68:394–424.
20. Aliberti C, Carandina R, Sarti D, Mulazzani L, Pizzirani E, Guadagni S, et al. Chemoembolization adopting polyethylene glycol drug-eluting embolics loaded with doxorubicin for the treatment of hepatocellular carcinoma. *Am J Roentgenol*. 2017;209:430–4.
21. Bruera G, Cannita K, Di Giacomo D, Lamy A, Frébourg T, Sabourin JC, et al. Worse prognosis of KRAS c.35 G > a mutant metastatic colorectal cancer (MCR) patients treated with intensive triplet chemotherapy plus bevacizumab (Flr-B/FOx). *BMC Med*. 2013;11:59.
22. Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Fiorella C, et al. The prevalent KRAS exon 2 c.35 G > a mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? *Crit Rev Oncol Hematol*. 2015;93:190–202.
23. Bruera G, Pepe F, Malapelle U, Pisapia P, Dal Mas A, Di Giacomo D, et al. KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCR) patients treated with first line Flr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. *Oncotarget*. 2018;9:26279–90.
24. Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, et al. Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal Cancer: a dose-finding and phase II study. *Oncol Rep*. 2010;23:1635–40.
25. Bruera G, Santomaggio A, Cannita K, Lanfiuti Baldi P, Tudini M, De Galitiis F, et al. "Poker" association of weekly alternating 5-fluorouracil, Irinotecan, bevacizumab and Oxaliplatin (Flr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. *BMC Cancer*. 2010;10:567.
26. Bruera G, Ricevuto E. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. *Lancet Oncol* 2010; 11:845-52. *Expert Opin Biol Ther*. 2011;11:821–4.
27. Bruera G, Cannita K, Giulianti F, Lanfiuti Baldi P, Vicentini R, Marchetti P, et al. Effectiveness of liver metastasectomies in metastatic colorectal Cancer (MCR) patients treated with triplet chemotherapy plus bevacizumab (Flr-B/FOx). *Clin Colorectal Cancer*. 2012;11:119–26.
28. Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Fenocchio E, et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial (abstract). *J Clin Oncol*. 2021;39(suppl 15) Abstract available online at <https://meetinglibrary.asco.org/record/195971/abstract> (Accessed on 08 June 2021).
29. Apostolou P, Ntanovasilis DA, Papisotiriou I. Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96 h after sample collection. *J Biol Res Thessalon*. 2017;24:11.
30. Toloudi M, Ioannou E, Chatziannou M, Apostolou P, Kiritsis C, Manta S, et al. Comparison of the growth curves of Cancer cells and Cancer stem cells. *Curr Stem Cell Res Ther*. 2014;9:112–6.
31. Apostolou P, Iliopoulos AC, Parsonidis P, Papisotiriou I. Gene expression profiling as a potential predictor between normal and cancer samples in gastrointestinal carcinoma. *Oncotarget*. 2019;10:3328–38.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2DDCT method. *Methods*. 2001;25:402–8.
33. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. *Cancer Res*. 1981;41:73–81.
34. Guadagni S, Fiorentini G, Clementi M, Palumbo P, Mambrini A, Masedu F. Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques. *Updat Surg*. 2017;69:403–10. <https://doi.org/10.1007/s13304-017-0480-6>.
35. Mambrini A, Bassi C, Pacetti P, Torri T, Iacono C, Ballardini M, et al. Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. *Pancreas*. 2008;36:56–60.
36. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45:228–47.
37. Guadagni S, Clementi M, Masedu F, Fiorentini G, Sarti D, Deraco M, et al. A pilot study of the predictive potential of chemosensitivity and gene expression assays using circulating tumour cells from patients with recurrent ovarian cancer. *Int J Mol Sci*. 2020;21:4813. <https://doi.org/10.3390/ijms21134813>.
38. Guadagni S, Fiorentini G, Papisotiriou I, Apostolou P, Masedu F, Sarti D, et al. Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study. *BMC Res Notes*. 2020;13:176.
39. Popova AA, Levkin PA. Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy. *Adv Therap*. 2020;3:1900100. <https://doi.org/10.1002/adtp.201900100>.
40. Blom K, Nygren P, Larsson R, Andersson CR. Predictive value of ex vivo Chemosensitivity assays for individualized Cancer chemotherapy: a Meta-analysis. *SLAS Technol*. 2017;22:306–14.
41. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar APN. Elimination of Colon Cancer stem-like cells by the combination of curcumin and FOLFOX. *Transl Oncol*. 2009;2:321–8.
42. Jensen SA, Vainer B, Witton CJ, Jørgensen JT, Sørensen JB. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and Dihydrofolate reductase in colorectal Cancer. *Acta Oncol*. 2008;47:1054–61.
43. Di Paolo A, Chu E. The role of thymidylate synthase as a molecular biomarker. *Clin Cancer Res*. 2004;10:411–2.
44. Farina AR, Cappabianca L, Sebastiano M, Zelli V, Guadagni S, Mackay AR. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. *J Exp Clin Cancer Res*. 2020;39:110. <https://doi.org/10.1186/s13046-020-01616-9>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.